French SME formulating conductive nanoinks for printed electronics, with expanding applications in medical implants, biosensors, and energy storage.
GENES'INK is a French SME specializing in the formulation and manufacturing of functional nanoinks and conductive inks for printed electronics. They develop ink formulations — including silver nanoparticle inks, transparent conductive inks, and biocompatible conductive inks — optimized for industrial printing processes like screen printing, inkjet, and roll-to-roll. Their work spans from scaling up nanomaterial-based inks for flexible electronics to applying conductive ink technology in medical devices, biosensors, and energy storage components.
Core contributor across BASMATI (scaling nanoinks), CLEARSILVER (transparent conductive electrodes with nanoinks), GREENSENSE (nanoink for biosensors), MADRAS (conductive inks, silver nanowires), and SBR (biocompatible conductive inks).
Involved in screen printing, inkjet, roll-to-roll, and in-mold printing processes across GREENSENSE, CLEARSILVER, MADRAS, and BASMATI.
SBR focuses on biocompatible conductive inks for smart bone regeneration implants; GREENSENSE applied inks to biosensing platforms for drug-of-abuse detection.
TEESMAT addressed electrochemical storage material characterization; GREENSENSE included battery components in its wireless biosensor platform.
BASMATI was explicitly about scaling up nanomaterials and inks for printing; CLEARSILVER targeted industrial manufacturing of nanoink-based electrodes.
In their early H2020 period (2015–2018), GENES'INK focused on core printed electronics capabilities: scaling nanoink production, developing transparent electrodes for organic electronics (CLEARSILVER), and building biosensor platforms using inkjet and screen printing (GREENSENSE). From 2019 onward, they diversified into higher-value application domains — smart bone regeneration implants with biocompatible inks (SBR), advanced material characterization for battery safety (TEESMAT), and next-generation organic electronics like photosensors and autonomous devices (MADRAS). The shift shows a company moving from ink formulation and process optimization toward applying their materials expertise in health, energy, and smart devices.
GENES'INK is expanding from pure ink formulation into application-driven domains — particularly biomedical implants and energy storage — where conductive inks enable smart, sensor-equipped products.
GENES'INK operates primarily as a specialist partner (5 of 6 projects), contributing ink formulation and printing expertise to larger consortia. They coordinated one project (CLEARSILVER, their largest at EUR 1.07M), which was an SME Instrument grant — indicating they can lead when the project centers on their core product. With 71 unique partners across 18 countries, they are well-networked and comfortable working in diverse, multinational teams rather than sticking to a small circle of repeat collaborators.
GENES'INK has collaborated with 71 unique partners across 18 countries, indicating broad European reach and a reputation as a trusted materials supplier in diverse consortia. Their network spans manufacturing, health, digital, and energy sectors.
GENES'INK occupies a rare niche: they are one of few European SMEs that both formulate functional nanoinks and understand how to optimize them for industrial-scale printing processes. This dual expertise — materials science plus manufacturing process knowledge — makes them a valuable bridge between lab-developed nanomaterials and real production lines. Their recent move into biocompatible conductive inks for medical implants opens a differentiated market position that few ink formulators can match.
